Antisense comes of age

Cancer and Metastasis Reviews

Volumn 17, Issue 2, 1998, Pages 169-176

  Flanagan, W Michael ^a  

^a Gilead Sciences ^*  (United States)

Author keywords

Anti cancer agents; Antisense therapeutics; Bcl 2; C raf; Ha ras; Phosphorothioate oligonucleotides; Protein kinase C

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CGP 69846A; GENE EXPRESSION MODULATOR 231; ISIS 2503; ISIS 3521; OBLIMERSEN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; ONCOPROTEIN; ONCOPROTEIN C RAF; PROTEIN BCL 2; PROTEIN KINASE C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER RESEARCH; CELL ONCOGENE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CARCINOMA; FATIGUE; GENE TECHNOLOGY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOGENE C RAF; ONCOGENE H RAS; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; OLIGONUCLEOTIDES, ANTISENSE;

EID: 0031847943     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006098218335     Document Type: Review

References (45)

1. Wagner RW: Gene inhibition using antisense oligodeoxynucleotides. Nature 372: 333-335, 1994
2. Stein CA, Krieg AM: Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res and Dev 4: 67-69, 1994
3. Stein CA: Phosphorothioate antisense oligonucleotides: Questions of specificity. Trends Biotechnol 14: 147-149, 1996
4. Stein CA: Does antisense exist? Nat Med 1: 1119-1121, 1995
5. Wagner RW, Flanagan WM: Antisense technology and prospects for therapy of infectious disease and cancer. Mol Med Today 3: 31-38, 1997
6. Wagner RW: The state of the art in antisense research. Nat Med 1: 1116-1118, 1995
7. Wagner RW: Toward a broad-based antisense technology. Antisense Res Dev 5: 113-114, 1995
8. Fisher TL, Terhorst T, Cao X, Wagner RW: Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells. Nucleic Acids Res 21: 3857-3865, 1993
9. Milner N, Mir KU, Southern EM: Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nature Bio 15: 537-541, 1997
10. Monia BP, Johnston JF, Greiger T, Muller M, Fabbro D: Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against c-raf kinase. Nat Med 2: 668-675, 1996
11. Moulds C, Lewis JG, Froehler BC, Grant D, Huang T, Milligan JF, Matteucci MD, Wagner RW: Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides. Biochemistry 34: 5044-5053, 1995
12. Flanagan WM, Su LL, Wagner RW: Elucidation of gene function using C-5 propyne antisense oligonucleotides. Nature Bio 14: 1139-1145, 1996
13. Flanagan WM, Kothavale A, Wagner RW: Effects of oligonucleotide length, mismatches, and mRNA levels on C-5 propyne-modified antisense potency. Nucleic Acids Res 24: 2936-2941, 1996
14. Coats S, Flanagan WM, Nourse J, Roberts JM: Requirement of p27Kip1 for Restriction Point Control of the Fibroblast Cell Cycle. Science 272: 877-880, 1996
15. St. Croix B, Floerenes VA, Rak J, Flanagan WM, Kerbel RS: Impact of p27kip1 on adhesion-dependent resistance of tumor cells to anti-cancer agents. Nat Med 2: 1204-1210, 1996
16. Ho SP, Bao Y, Lesher T, Malhotra R, Ma LY, Fluharty SJ, Sakai RR: Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nature Bio 16: 59-63, 1998
17. Patzel V, Sczakeil G: Theoretical design of antisense RNA structures substantially improves annealing kinetics and efficacy in human cells. Nature Bio 16: 64-68, 1998
18. Bennett CF, Chiang MY, Chan H, Shoemaker JE, Mirabelli CK: Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 41: 1023-1033, 1992
19. Lewis JG, Lin KY, Kothavale A, Flanagan WM, Matteucci MD, DePrince RB, Mook RA, Hendren RW, Wagner RW: A serum-resistant cytofectin for cellular delivery of antisense oligonucleotides and plasmid DNA. Proc Natl Acad Sci USA 93: 3176-3181, 1996
20. Wagner RW, Matteucci MD, Lewis JG, Gutierrez AJ, Moulds C, Froehler BC: Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science 260: 1510-1513, 1993
21. Flanagan WM, Wagner RW: Potent and selective gene inhibition using antisense oligonucleotides. Mol Cell Biochem 172: 213-225, 1997
22. McGraw K, McKay R, Miraglia L, Boggs RT, Pribble JP, Muller M, Geiger T, Fabbro D, Dean NM: Antisense oligonucleotide inhibitors of isozymes of protein kinase C: In vitro and in vivo activity, and clinical development as anti-cancer therapeutics. Anti-cancer Drug Design 12: 315-327, 1997
23. Dean N, McKay R, Miraglia L, Howard R, Cooper S, Giddings J, Nicklin P, Meister L, Ziel R, Geiger T, Muller M, Fabbro D: Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-alpha expression. Cancer Res 56: 3499-3507, 1996
24. Stepkowski SM, Tu Y, Condon TP, Bennett CF: Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. J Immunol: 5336-5346, 1994
25. Yazaki T, Ahmad S, Chahlavi A, Zylber-Katz E, Dean NM, Rabkin SD, Martuza RL, Glazer RI: Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-a phosphorothioate oligodeoxynucleotide. Mol Pharm 50: 236-242, 1997
26. Dean NM, McKay R, Condon TP, Bennett CF: Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem 269: 16416-16424, 1994
27. McKay R, Dean MN: Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate. Proc Natl Acad Sci USA 91: 1762-1766, 1994
28. Stewart A: Antisense against protein kinase C-α mRNA makes sense for cancer therapy? Mol Med Today 3: 324, 1997
29. Monia BP: First- and second-generation antisense inhibitors targeted to human c-raf kinase: In vitro and in vivo studies. Anti-cancer Drug Design 12: 327-341, 1997
30. Monia BP, Johnston JF, Ecker DJ, Zounes MA, Lima WF, Freier SM: Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J Biol Chem 267: 19954-19962, 1992
31. Cowsert LM: In vitro and in vivo activity of antisense inhibitors of ras: Potential for clinical development. Anti-cancer Drug Design 12: 359-371, 1997
32. Cotter FE, Johnson P, Hall P, Pocock C, al Mahdi N, Cowell JK, Morgan G: Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 9: 3049-3055, 1994
33. Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M, Dziewanowska Z: Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. The Lancet 349: 1137-1141, 1997
34. Raynaud FI, Orr RM, Goddard PM, Lacey HA, Lancashire H, Judson IR, Beck T, Bryan B, Cotter FE: Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther 281: 420-127, 1997
35. Geary RS, Leeds JM, Henry SP, Monteith DK, Levin AA: Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anti-cancer Drug Design 12: 383-393, 1997
36. Henry SP, Montieth D, Levin AA: Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligonucleotidess. Anti-cancer Drug Design 12: 395-407, 1997
37. Henry SP, Monteith D, Bennett F, Levin AA: Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-a and c-raf kinase. Anti-cancer Drug Design 12: 409-420, 1997
38. Monteith DK, Henry SP, Howard RB, Flournov S, Levin AA, Bennett CF, Crooke ST: Immune stimulation: A class effect of phosphothioate oligodeoxynucleotides in rodents. Anti-cancer Drug Design 12: 421-431, 1997
39. Galbraith WM, Hobson WC, Giclas PC, Schechter PJ, Agrawal S: Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev 4: 201-206, 1994
40. Shaw DR, Rustagi PK, Kandimalla ER, Manning AN, Jiang Z, Agrawal S: Effects of synthetic oligonucleotides on human complement and coagulation. Biochem Pharmacol 53: 1123-1132, 1997
41. Zhang R, Yan J, Shahinian H, Amin G, Lu Z, Liu T, Saag MS, Jiang Z, Temsamani J, Martin RR, Schechter PJ, Agrawal S, Diasio RB: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM91) in HIV-infected subjects. Clin Pharmacol Ther 58: 44-53, 1995
42. Zhao Q, Temsamani J, Iadarola PL, Jiang Z, Agrawal S: Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol 51: 173-180, 1996
43. Altmann KH, Dean NM, Fabbro D, Freier SM, Geiger T, Haner R, Husken D, Martin P, Monia BP, Muller M, Natt F, Nicklin P, Phillips J, Pieles U, Sasmor H, Moser HE: Second generation of antisense oligonucleotides: From nuclease resistance to biological efficacy in animals. Chemia 50: 168-176, 1996
44. Altmann KH, Fabbro D, Dean NM, Geiger T, Monia BP, Muller M, Nicklin P: Second-generation antisense oligonucleotides: Structure-activity relationships and the design of improved signal-transduction inhibitors. Biochemical Society Transactions 24: 630-637, 1996
45. Tortora G, Caputo R, Damiano V, Bianco R, Pepe S, Bianco AR, Jiang Z, Agrawal S, Ciardiello F: Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. Proc Natl Acad Sci USA 94: 12586-12591, 1997